<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874119</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-MISP-50440, 23432</org_study_id>
    <nct_id>NCT01874119</nct_id>
  </id_info>
  <brief_title>Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma</brief_title>
  <acronym>HDIL2/Emend</acronym>
  <official_title>Phase 2B Double Blind Placebo Controlled Crossover Study Evaluating the Efficacy of IV Fosaprepitant for Chemo Induced N/V With High Dose Interleukin 2 for Metastatic Melanoma and Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant
      therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD
      IL-2) therapy for metastatic melanoma or metastatic renal cell carcinoma. Fosaprepitant is an
      intravenous (IV) medication that is FDA- approved for use in adults for the prevention of
      nausea and vomiting during chemotherapy. Fosaprepitant works by blocking the neurokinin-1
      receptor, which is a receptor in the brain that is known to cause nausea and vomiting. Past
      studies estimate that up to 70% of patients undergoing treatment with HD IL-2 will have
      nausea and/or vomiting. While fosaprepitant has been used in clinical practice to treat
      nausea and vomiting during HD IL-2, there have not been any studies done to see how well it
      works. All patients will receive treatment (IV fosaprepitant) during the study during either
      the first or second hospital admission for HD IL-2. On the admission that the subject is not
      receiving IV fosaprepitant, the subject will receive placebo (a medicine that looks like
      fosaprepitant, but is not active). The study is double-blinded, which means neither the
      subject, nor the study doctor will know to which group you have been assigned to that
      admission (IV fosaprepitant or placebo). This study design was chosen to limit the potential
      for bias, which means the trial was designed to try to ensure that unknown factors do not
      affect trial results. When patients start the study, patients will be randomly assigned to
      one of two groups: those who receive treatment (IV fosaprepitant) first and those who receive
      placebo first. During the first admission, subjects will be given the IV fosaprepitant or IV
      placebo during admission. During the second admission, subjects will 'crossover' and receive
      the other treatment that they did not receive during the first admission. Improvement in
      nausea and vomiting will be assessed by counting the number of nausea and vomiting episodes,
      recording if the subject needs additional medication for nausea and vomiting, and by using
      patient questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2B double-blind placebo-controlled crossover study evaluating the efficacy of
      intravenous fosaprepitant for chemotherapy-induced nausea and vomiting in patients undergoing
      high-dose interleukin-2 (HD IL-2) therapy (720,000 IU/kg per dose intravenously; 14 doses, 2
      cycles per course) for metastatic melanoma and metastatic renal cell carcinoma. A total of 22
      subjects will be enrolled in the study. On study entry, patients will be randomized to
      receive either IV fosaprepitant (150 mg on Day 1, Day 3, or Day 5) or matched placebo during
      first admission of HD IL-2 therapy (cycle 1). All subjects will crossover and receive the
      opposite treatment during cycle 2. All patients will receive ondansetron 24 mg by mouth daily
      per standard protocol every 24 hours during Days 1-5 of admission starting 30 minutes prior
      to first dose of HD IL-2. During the treatment phase, subjects will receive Patients will
      receive IV fosaprepitant 30 minutes before first dose of HD IL-2 therapy and every 48 hours
      until completion of HD IL-2 therapy. Upon study entry, the subjects will be given a dairy to
      report episodes of vomiting, use of rescue therapy, and nausea assessments using the 1-100
      scale within the visual analogue scale (VAS). The subject will be instructed to complete
      entries from baseline assessment (prior to first dose) until 5 days after last dose of HD
      IL-2 for endpoint analysis. During inpatient admissions, subjects will complete diary entries
      before each dose (q8 hours). As an outpatient, subjects will complete diary entries on a
      daily basis. Recording of whether or not pruritus was observed will also be collected within
      the subject diary. If a patient reports pruritus, the severity of pruritus on the 1-100 scale
      visual analogue scale (VAS) will also be collected. The study team will record any episodes
      of vomiting and the use of rescue therapy and ensure completion of patient diary during
      inpatient portion. Assessments will be made via telephone contact to determine onset of any
      episodes of CINV during outpatient portion. Safety assessments including adverse events (AEs)
      monitoring will be performed and assessed using Common Terminology Criteria for Adverse
      Events (CTCAE) version 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment issues
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 3, 2015</completion_date>
  <primary_completion_date type="Actual">December 3, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Complete Response During Inpatient Admission</measure>
    <time_frame>From the initiation of through 48 hours following the final dose of Interleukin-2</time_frame>
    <description>No vomiting from the initiation of through 48 hours following the final dose of HD IL-2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
    <arm_group_label>Fosaprepitant</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following inclusion criteria to be eligible for
             enrollment into the study:

               1. Evidence of a personally signed and dated informed consent document indicating
                  that the subject (or legally acceptable representative) has been informed of all
                  pertinent aspects of the trial.

               2. Subjects who are willing to comply with scheduled visits, treatment plan,
                  laboratory tests, and other study procedures.

               3. Be at least 18 years of age at the time of informed consent.

               4. Has a diagnosis of metastatic melanoma or metastatic renal cell carcinoma and who
                  will undergo high-dose interleukin-2 (HD IL-2) therapy

               5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
                  at Baseline/Day 1 visit. (See Appendix 6 on p. 51, ECOG Performance Status)

               6. Female of reproductive potential must agree use non-hormonal methods to avoid
                  pregnancy during study participation and for 1 month after last dose of study
                  drug

        Exclusion Criteria:

          -  Subjects presenting with any of the following will not be included in the study:

               1. Women who are pregnant or lactating, or planning pregnancy

               2. Women of childbearing potential who refuse to use non-hormonal methods to avoid
                  pregnancy

               3. Known hypersensitivity to any component of fosaprepitant or aprepitant

               4. Have taken pimozide or cisapride &lt;4 weeks, cytochrome P450 3A4 inducers within 30
                  days, strong CYP3A4 inhibitors within 7 days, or antiemetics within 48 hours
                  prior to treatment initiation (See Appendix 7 on p. 52 for list of CYP3A4
                  inducers and strong CYP3A4 inhibitors)

               5. Have evidence of clinically significant and unstable diseases or conditions such
                  as cardiovascular, immunosuppressive, hematologic, hepatic, neurologic, renal,
                  endocrine, collagen-vascular, or gastrointestinal abnormalities that the
                  investigator thinks may interfere with study participation

               6. Participation in other study using an investigational or experimental therapy or
                  procedure within 4 weeks or 5 half-lives (whichever is longer) before study entry

               7. Subjects cannot participate in studies of other investigational or experimental
                  therapies or procedures at any time during their participation in this study.

               8. Other severe acute or chronic medical or psychiatric condition or laboratory
                  abnormality that may increase the risk associated with study participation or may
                  interfere with the interpretation of study results and, in the judgment of the
                  investigator, would make the subject inappropriate for entry into this study.

               9. Subjects who are investigational site staff members or who are Sponsor employees
                  directly involved in the conduct of the trial.

              10. A subject who, in the opinion of the investigator or sponsor, will be
                  uncooperative or unable to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Richart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Louis University, Department of Internal Medicine, Division of Hematology and Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.</citation>
    <PMID>21383291</PMID>
  </reference>
  <reference>
    <citation>Van Laere K, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, Declercq R, Sanabria Bohorquez SM, Hamill T, Mozley PD, Tatosian D, Xie W, Liu Y, Liu F, Zappacosta P, Mahon C, Butterfield KL, Rosen LB, Murphy MG, Hargreaves RJ, Wagner JA, Shadle CR. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012 Aug;92(2):243-50. doi: 10.1038/clpt.2012.62. Epub 2012 Jun 27.</citation>
    <PMID>22739139</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <results_first_submitted>January 31, 2018</results_first_submitted>
  <results_first_submitted_qc>April 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2018</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>John Richart, M.D.</investigator_full_name>
    <investigator_title>Associate Professor, Dept. of Internal Medicine, Hematology and Oncology</investigator_title>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fosaprepitant First, Then Placebo</title>
          <description>Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Placebo: During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Fosaprepitant</title>
          <description>Placebo: During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Participants Completing All Cycles</title>
          <description>Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Placebo: intravenous 0.9% saline every 48 hours during 6-day hospital admission</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="37" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Complete Response During Inpatient Admission</title>
        <description>No vomiting from the initiation of through 48 hours following the final dose of HD IL-2</description>
        <time_frame>From the initiation of through 48 hours following the final dose of Interleukin-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant</title>
            <description>During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Response During Inpatient Admission</title>
          <description>No vomiting from the initiation of through 48 hours following the final dose of HD IL-2</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the initiation of through 48 hours following the final dose of HD IL-2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fosaprepitant</title>
          <description>During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper GI hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder - Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Uncal herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoalbunemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed. Caution is advised for any future investigation with this combination in regards to toxicity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. John Richart</name_or_title>
      <organization>Saint Louis University</organization>
      <phone>314-577-8854</phone>
      <email>richartj@slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

